Tumor antigen release and immune system activation

"Tumor antigen release and immune system activation" is not a single molecular entity or canonical drug target. Instead, it describes the biological process whereby dying tumor cells—often as a result of therapy—release antigens that can be recognized by the immune system. This leads to the recruitment and activation of various immune cell types through pro-inflammatory cytokines and chemokines. Therapies such as oncolytic viruses induce immunogenic cell death in tumors, resulting in both direct killing of cancer cells and stimulation of an anti-tumor immune response through increased presentation of tumor-associated antigens (TAAs) by dendritic cells and other antigen-presenting cells. This dual effect can convert an immunosuppressive ("cold") tumor microenvironment into an inflamed ("hot") one that is more responsive to further immunotherapy interventions[1][2]. However, "tumor antigen release/immune system activation" itself does not refer to a discrete protein or receptor but rather encompasses multiple pathways involved in anti-tumor immunity. Note: The entry "Tumor antigen release/immune system activation" is not itself a canonical therapeutic target like an enzyme or receptor; it refers instead to interconnected processes central to many modern cancer therapies. For structured data purposes, this should be flagged as incorrect for use as a molecular drug target name[1][2].

Induction of immunogenic cell death leading to tumor antigen release[2] Activation of innate and adaptive immune responses via cytokine/chemokine production[2] Uptake and cross-presentation of tumor antigens by antigen-presenting cells[2]